Flag of the European Union EU Clinical Trials Register Help

Clinical trials for celltrion

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    68 result(s) found for: celltrion. Displaying page 2 of 4.
    « Previous 1  2  3  4  Next»
    EudraCT Number: 2018-000187-28 Sponsor Protocol Number: POLE-1 Start Date*: 2020-10-20
    Sponsor Name:University Hospital Ulm
    Full Title: Pembrolizumab in Marginal Zone Lymphoma - a multicenter open label single-arm phase II study
    Medical condition: Marginal Zone Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10076596 Marginal zone lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) AT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2013-004544-32 Sponsor Protocol Number: CT-P27/2.1 Start Date*: 2014-02-10
    Sponsor Name:Celltrion, Inc
    Full Title: Randomized, double-blind, placebo-controlled, single-centre, phase IIa study in healthy volunteers to evaluate the efficacy and safety of CT-P27 in an influenza challenge model
    Medical condition: Influenza
    Disease: Version SOC Term Classification Code Term Level
    16.1 10021881 - Infections and infestations 10022000 Influenza PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2020-003369-20 Sponsor Protocol Number: CT-P59_3.2 Start Date*: 2020-11-13
    Sponsor Name:Celltrion, Inc
    Full Title: A Phase 2/3, Randomized, Parallel-group, Placebo-controlled, Double-Blind Study to Evaluate the Efficacy and Safety of CT-P59 in Combination with Standard of Care in Outpatients with Severe Acute R...
    Medical condition: SARS CoV 2 infection in outpatients
    Disease: Version SOC Term Classification Code Term Level
    23.0 10022891 - Investigations 10084271 SARS-CoV-2 test positive PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) RO (Completed) HU (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2022-002928-12 Sponsor Protocol Number: CT-P47_3.2 Start Date*: 2023-01-26
    Sponsor Name:CELLTRION, Inc.
    Full Title: A Single-arm, Open-label, Multiple-dose, Phase 3 Study to Evaluate Usability of Subcutaneous Auto-injector of CT-P47 in Patients with Moderate to Severe Active Rheumatoid Arthritis
    Medical condition: Moderate to severe active rheumatoid arthritis (RA) diagnosed according to the 2010 American College of Rheumatology (ACR)/European Alliance of Associations for Rheumatology (EULAR) classification ...
    Disease: Version SOC Term Classification Code Term Level
    23.1 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: View results
    EudraCT Number: 2022-001066-36 Sponsor Protocol Number: CT-P47_3.1 Start Date*: 2022-07-17
    Sponsor Name:CELLTRION, Inc.
    Full Title: A Randomized, Active-Controlled, Double-Blind, Phase 3 Study to Compare Efficacy and Safety of Two Intravenous Infusion Formulations of Tocilizumab (CT-P47 and RoActemra) when Co-administered with ...
    Medical condition: Moderate to severe active rheumatoid arthritis (RA) diagnosed according to the 2010 American College of Rheumatology (ACR)/European Alliance of Associations for Rheumatology (EULAR) classification ...
    Disease: Version SOC Term Classification Code Term Level
    23.1 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: View results
    EudraCT Number: 2014-005324-10 Sponsor Protocol Number: CT-P10_3.4 Start Date*: 2015-08-20
    Sponsor Name:CELLTRION, Inc.
    Full Title: A Phase 3, Randomised, Parallel-Group, Active-Controlled, Double-Blind Study to Compare Efficacy and Safety between CT-P10 and Rituxan in Patients with Low Tumour Burden Follicular Lymphoma
    Medical condition: Low Tumour Burden Follicular Lymphoma.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065856 Non-Hodgkin's lymphoma unspecified histology indolent PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) LV (Completed) ES (Completed) PT (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2013-004555-21 Sponsor Protocol Number: CT-P103.2 Start Date*: 2014-04-07
    Sponsor Name:CELLTRION, Inc.
    Full Title: A Randomized, Controlled, Double-Blind, Parallel-Group, Phase 3 Study to Compare the Pharmacokinetics, Efficacy and Safety between CT-P10, Rituxan and MabThera in Patients with Rheumatoid Arthritis
    Medical condition: Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004870 10039075 Rheumatoid arthritis and associated conditions HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) LV (Completed) PT (Completed) DE (Completed) SK (Completed) HU (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2014-004904-31 Sponsor Protocol Number: IFX4501 Start Date*: 2015-05-19
    Sponsor Name:Mundipharma Pharmaceuticals B.V.
    Full Title: An open-label, multicentre, phase IV study to investigate the infliximab serum concentration of Remsima™ (infliximab biosimilar) after switching from Remicade (infliximab) in subjects with Crohn’s ...
    Medical condition: Crohn’s Disease (CD), Ulcerative Colitis (UC) or Rheumatoid Arthritis (RA).
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing) BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-000469-33 Sponsor Protocol Number: NL.76663.018.21 Start Date*: 2021-10-12
    Sponsor Name:Amsterdam UMC location AMC
    Full Title: A Prospective Multicenter Randomized Controlled, Open-label Study to Compare the Efficacy of Subcutaneous Infliximab Monotherapy with Subcutaneous Infliximab and Concomitant Immunosuppression in th...
    Medical condition: Crohns disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-002125-11 Sponsor Protocol Number: CT-P13-3.5 Start Date*: 2016-08-23
    Sponsor Name:Celltrion, Inc
    Full Title: A Randomized, Parallel-Group, Phase I/III Study to Evaluate Efficacy, Pharmacokinetics and Safety between Subcutaneous CT-P13 and Intravenous CT-P13 in Patients with Active Rheumatoid Arthritis
    Medical condition: Active Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Completed) EE (Completed) HU (Completed) CZ (Completed) BG (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2009-016197-33 Sponsor Protocol Number: 3.1 Start Date*: 2010-02-25
    Sponsor Name:Celltrion, Inc.
    Full Title: A Double-blind, Randomised, Parallel Group, Phase III Study to Demonstrate Equivalent Efficacy and Comparable Safety of CT-P6 and Herceptin, Both in Combination with Paclitaxel, in Patients with Me...
    Medical condition: Metastatic breast cancer
    Disease: Version SOC Term Classification Code Term Level
    13.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: AT (Completed) PL (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2019-000668-27 Sponsor Protocol Number: MBW-2017-01 Start Date*: 2019-09-19
    Sponsor Name:Marta Maia Boscá Watts
    Full Title: Pilot Project for the Treatment of Perianal Disease through the Local Injection of Remsima Guided by Ultrasound. Number of cases.
    Medical condition: Perianal disease (PD): alteration associated with inflammatory bowel disease (IBD) that includes fissures, ulcers, fistulas or abscesses, and is one of the most difficult aspects of treating IBD. B...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-004173-32 Sponsor Protocol Number: 1-10-72-164-15 Start Date*: 2015-12-18
    Sponsor Name:Department of Clinical Biochemestry, Aarhus University Hospital
    Full Title: Personalized medicine: Administration of TNF-alpha inhibitor treatment due to serum concentration measuring. A randomized and investigator initiated study.
    Medical condition: Rheumatic diseases
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000005156 10039075 Rheumatoid arthritis and associated conditions HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-002700-21 Sponsor Protocol Number: OOI/Onkocytogenetika/2022/01 Start Date*: 2023-02-28
    Sponsor Name:National Institute of Oncology [...]
    1. National Institute of Oncology
    2. National Institute of Oncology
    Full Title: An open label, Phase IV study to assess immunological changes in patients with glioblastoma multiforme treated with bevacizumab infusion
    Medical condition: Glioblastoma multiforme
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2022-003588-55 Sponsor Protocol Number: 20221102 Start Date*: 2024-10-14
    Sponsor Name:Isala
    Full Title: Evaluating the safety of shortened infusion tiMes for dIfferent oNcological immUnoThErapies; An observational prospective study
    Medical condition: Oncology
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-002813-12 Sponsor Protocol Number: CT-P103.1 Start Date*: 2011-12-30
    Sponsor Name:CELLTRION, Inc
    Full Title: A Phase 3, Randomized, Parallel-Group, Active-Controlled, Double-Blind Study to Compare the Efficacy and Safety of CT-P10 With MabThera, Each Administered in Combination With Cyclophosphamide, Vinc...
    Medical condition: Advanced Follicular Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10016910 Follicle centre lymphoma, follicular grade I, II, III stage IV PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10016909 Follicle centre lymphoma, follicular grade I, II, III stage III PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Prematurely Ended) HU (Prematurely Ended) GR (Prematurely Ended) ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-004199-16 Sponsor Protocol Number: ME-401-004 Start Date*: 2021-03-18
    Sponsor Name:MEI Pharma, Inc.
    Full Title: A Phase 3, Randomized, Open-Label, Controlled, Multicenter Study of Zandelisib (ME-401) in Combination with Rituximab Versus Standard Immunochemotherapy in Patients with Relapsed Indolent Non-Hodgk...
    Medical condition: Relapsed or refractory follicular lymphoma (FL) or marginal zona lymphoma (MZL)
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029473 Nodular (follicular) lymphoma LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10076596 Marginal zone lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) FR (Prematurely Ended) BE (Prematurely Ended) NL (Prematurely Ended) GR (Prematurely Ended) IT (Prematurely Ended) ES (Temporarily Halted)
    Trial results: View results
    EudraCT Number: 2020-004407-13 Sponsor Protocol Number: INCMOR0208-301 Start Date*: 2021-06-17
    Sponsor Name:Incyte Corporation
    Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to Rituximab Versus Lenalidomide in Addit...
    Medical condition: follicular lymphoma (FL) and marginal zone lymphoma (MZL)
    Disease: Version SOC Term Classification Code Term Level
    24.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10080213 In situ follicular lymphoma LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10076596 Marginal zone lymphoma PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Trial now transitioned) CZ (Trial now transitioned) FR (Trial now transitioned) DE (Trial now transitioned) IE (Trial now transitioned) AT (Trial now transitioned) NL (Trial now transitioned) SE (Trial now transitioned) HU (Trial now transitioned) DK (Trial now transitioned) NO (Trial now transitioned) FI (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2009-014463-39 Sponsor Protocol Number: 1.1 Start Date*: 2009-12-01
    Sponsor Name:Celltrion, Inc.
    Full Title: A Double-blind Randomised, Parallel Phase I/IIb Study to Evaluate Initial Safety and Efficacy, Comparative Pharmacokinetics and Immunogenicity for CT-P6 and Herceptin in Metastatic Breast Cancer
    Medical condition: Metastatic breast cancer
    Disease: Version SOC Term Classification Code Term Level
    12.0 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: LV (Completed) BG (Completed) GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2020-000241-14 Sponsor Protocol Number: ADCT-402-311 Start Date*: 2021-01-26
    Sponsor Name:ADC Therapeutics SA
    Full Title: A Phase 3 Randomized Study of Loncastuximab Tesirine Combined with Rituximab Versus Immunochemotherapy in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (LOTIS-5)
    Medical condition: Diffuse Large B-Cell Lymphoma (DLBCL)
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012818 Diffuse large B-cell lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Trial now transitioned) CZ (Trial now transitioned) FR (Trial now transitioned) IT (Trial now transitioned) NL (Trial now transitioned) HU (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 04 06:28:05 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA